Free Trial
NASDAQ:ELVN

Enliven Therapeutics Q1 2024 Earnings Report

Enliven Therapeutics logo
$20.36 -0.32 (-1.55%)
Closing price 04:00 PM Eastern
Extended Trading
$20.36 0.00 (-0.02%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enliven Therapeutics EPS Results

Actual EPS
-$0.54
Consensus EPS
-$0.58
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Enliven Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Enliven Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Tuesday, May 14, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Enliven Therapeutics' Q3 2025 earnings is scheduled for Wednesday, November 12, 2025, with a conference call scheduled on Friday, November 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Enliven Therapeutics Earnings Headlines

Lifesci Capital Has Positive Outlook for ELVN Q3 Earnings
A New Way to Double Your Retirement Income?
Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.tc pixel
See More Enliven Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enliven Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enliven Therapeutics and other key companies, straight to your email.

About Enliven Therapeutics

Enliven Therapeutics (NASDAQ:ELVN), a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

View Enliven Therapeutics Profile

More Earnings Resources from MarketBeat